rs771847879

Variant summary

Our verdict is Benign. The variant received -10 ACMG points: 0P and 10B. BP4_ModerateBP6_Very_Strong

The NM_000264.5(PTCH1):​c.101G>C​(p.Arg34Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000044 in 1,589,322 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R34K) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.000026 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000021 ( 0 hom. )

Consequence

PTCH1
NM_000264.5 missense

Scores

2
1
16

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:2

Conservation

PhyloP100: 3.13

Publications

1 publications found
Variant links:
Genes affected
PTCH1 (HGNC:9585): (patched 1) This gene encodes a member of the patched family of proteins and a component of the hedgehog signaling pathway. Hedgehog signaling is important in embryonic development and tumorigenesis. The encoded protein is the receptor for the secreted hedgehog ligands, which include sonic hedgehog, indian hedgehog and desert hedgehog. Following binding by one of the hedgehog ligands, the encoded protein is trafficked away from the primary cilium, relieving inhibition of the G-protein-coupled receptor smoothened, which results in activation of downstream signaling. Mutations of this gene have been associated with basal cell nevus syndrome and holoprosencephaly. [provided by RefSeq, Aug 2017]
PTCH1 Gene-Disease associations (from GenCC):
  • basal cell nevus syndrome 1
    Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
  • holoprosencephaly 7
    Inheritance: AD Classification: DEFINITIVE, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), G2P
  • nevoid basal cell carcinoma syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Orphanet
  • holoprosencephaly
    Inheritance: AD Classification: LIMITED Submitted by: Illumina

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -10 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.1732297).
BP6
Variant 9-95508261-C-G is Benign according to our data. Variant chr9-95508261-C-G is described in ClinVar as Benign. ClinVar VariationId is 524561.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PTCH1NM_000264.5 linkc.101G>C p.Arg34Thr missense_variant Exon 1 of 24 ENST00000331920.11 NP_000255.2
PTCH1NM_001083603.3 linkc.199-1662G>C intron_variant Intron 1 of 23 ENST00000437951.6 NP_001077072.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PTCH1ENST00000331920.11 linkc.101G>C p.Arg34Thr missense_variant Exon 1 of 24 5 NM_000264.5 ENSP00000332353.6
PTCH1ENST00000437951.6 linkc.199-1662G>C intron_variant Intron 1 of 23 5 NM_001083603.3 ENSP00000389744.2

Frequencies

GnomAD3 genomes
AF:
0.0000264
AC:
4
AN:
151672
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000966
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000142
AC:
3
AN:
210536
AF XY:
0.0000171
show subpopulations
Gnomad AFR exome
AF:
0.000263
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000209
AC:
3
AN:
1437650
Hom.:
0
Cov.:
34
AF XY:
0.00000140
AC XY:
1
AN XY:
714008
show subpopulations
African (AFR)
AF:
0.0000618
AC:
2
AN:
32352
American (AMR)
AF:
0.00
AC:
0
AN:
42908
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25682
East Asian (EAS)
AF:
0.00
AC:
0
AN:
38230
South Asian (SAS)
AF:
0.0000119
AC:
1
AN:
84022
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
47534
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
4556
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
1103080
Other (OTH)
AF:
0.00
AC:
0
AN:
59286
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.508
Heterozygous variant carriers
0
1
1
2
2
3
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000264
AC:
4
AN:
151672
Hom.:
0
Cov.:
32
AF XY:
0.0000270
AC XY:
2
AN XY:
74056
show subpopulations
African (AFR)
AF:
0.0000966
AC:
4
AN:
41416
American (AMR)
AF:
0.00
AC:
0
AN:
15248
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3452
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5178
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4834
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10510
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
314
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
67726
Other (OTH)
AF:
0.00
AC:
0
AN:
2082
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.525
Heterozygous variant carriers
0
1
1
2
2
3
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00
Hom.:
0
Bravo
AF:
0.0000416
ExAC
AF:
0.0000258
AC:
3

ClinVar

Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Gorlin syndrome Benign:1
Dec 09, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hereditary cancer-predisposing syndrome Benign:1
Dec 06, 2022
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.31
BayesDel_addAF
Benign
-0.26
T
BayesDel_noAF
Benign
-0.31
CADD
Benign
23
DANN
Benign
0.70
DEOGEN2
Benign
0.18
T
Eigen
Benign
-0.67
Eigen_PC
Benign
-0.62
FATHMM_MKL
Uncertain
0.82
D
LIST_S2
Benign
0.55
T
M_CAP
Pathogenic
0.96
D
MetaRNN
Benign
0.17
T
MetaSVM
Benign
-0.52
T
MutationAssessor
Benign
0.69
N
PhyloP100
3.1
PrimateAI
Pathogenic
0.92
D
PROVEAN
Benign
0.020
N
REVEL
Benign
0.23
Sift
Benign
0.61
T
Sift4G
Benign
0.40
T
Polyphen
0.089
B
Vest4
0.26
MutPred
0.33
Gain of phosphorylation at R34 (P = 0.0045);
MVP
0.53
MPC
1.0
ClinPred
0.014
T
GERP RS
1.3
PromoterAI
0.019
Neutral
Varity_R
0.067
gMVP
0.71
Mutation Taster
=79/21
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs771847879; hg19: chr9-98270543; API